GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
GeneDx Holdings Corp. - Class A (WGS)
Company Research
Source: GlobeNewswire
Reported first quarter 2024 revenue from continuing operations1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins2 from continuing operations to 61% Narrowed first quarter 2024 adjusted net loss2 to $8.5M and delivered 71% year-over-year cash burn reduction Raised guidance to deliver between $235M and $245M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ET STAMFORD, Conn., April 29, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2024. “Our strong first quarter results reflect our continued dedication to our three key organizational focuses: growing exome and genome revenue, increasing our average reimbursement rates while expanding access to testing, and meaningfully reducing o
Show less
Read more
Impact Snapshot
Event Time:
WGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WGS alerts
High impacting GeneDx Holdings Corp. - Class A news events
Weekly update
A roundup of the hottest topics
WGS
News
- GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at TD Cowen from $14.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
- GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at BTIG Research from $15.00 to $19.00. They now have a "buy" rating on the stock.MarketBeat
- GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease DatasetGlobeNewswire
- GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at BTIG Research from $11.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $6.00 to $11.00. They now have a "neutral" rating on the stock.MarketBeat
WGS
Earnings
- 4/29/24 - Miss
WGS
Sec Filings
- 5/15/24 - Form 4
- 5/3/24 - Form 4
- 4/30/24 - Form 4
- WGS's page on the SEC website